SK bioscience: "AI Introduced in Vaccine Production to Expand into R&D and Quality Control"

AI-based yield management system for influenza vaccine production
Analyzes production data to optimize process operations
Driving enterprise-wide AI transformation... strengthening global partnerships

SK bioscience introduced examples of vaccine production innovations using artificial intelligence (AI) and its plans for an enterprise-wide AI transformation (AX). The company plans to expand its use of AI, which began on the production floor, across research and development, quality control, and other business functions to improve work efficiency and strengthen its global competitiveness in vaccines.

SK bioscience said it presented its current use of AI and future plans at the “AI-Bio New Drug Hub Global Summit Incheon,” held on October 23 at INSPIRE Entertainment Resort on Yeongjong Island, Incheon.

SK bioscience presented its current use of artificial intelligence (AI) and future plans at the “AI-Bio Drug Discovery Hub Global Summit Incheon,” held on the 23rd at Inspire Entertainment Resort on Yeongjongdo, Incheon. SK bioscience.

The event was organized to explore innovations in drug development through the convergence of AI and biotechnology, as well as ways for domestic and international companies to collaborate. At the event, SK bioscience shared its experience using AI in actual vaccine production and outlined how it could contribute to innovation in the AI-based bio industry and the development of its ecosystem.

SK bioscience uses AI technology to improve efficiency and stability in vaccine production. At its L HOUSE facility in Andong, North Gyeongsang Province, it has applied an AI-based “Yield Guide Agent” to the influenza vaccine production process. The system analyzes production data to identify factors affecting yields and recommends conditions for more efficient process operations. This helps production staff assess process conditions and make decisions based on data. Key decisions are made following review and approval by the relevant personnel.

Building on its experience on the production floor, SK bioscience is expanding the scope of AI applications to various business areas. In research and development, it is using AI to support information gathering and research work. In clinical development and regulatory affairs, it is working to improve the efficiency of related tasks, while in quality control, it is exploring ways to use AI for repetitive work such as preparing documents and responding to inspections.

Lee Yong, head of the AX Planning Team at SK bioscience, said, “Alongside pursuing projects using our own capabilities, we are also working with global partners such as the Gates Foundation and PATH. Going forward, we plan to connect the data and knowledge from each business function to create an environment where AI and people work together.”

This content was produced with the assistance of AI translation services.